Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Below averageAlkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. We have a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy, and a pipeline of clinical and preclinical candidates in development for neurological disorders. Headquartered in Ireland, we also have a corporate office and R&D center in Massachusetts and a manufacturing facility in Ohio.
In the company’s own words · 10-K filed Feb 25, 2026 · SEC EDGAR
Business segments
Jun 2026 · $544.4MThe company’s own SEC segment disclosure.
- Vivitrol$124.5M23%
- Aristada And Aristada Initio$96.7M18%
- LUMRYZ$96.6M18%
- LYBALVI$94.0M17%
- Manufactured Product And Royalty$84.3M15%
- Royalty$27.5M5%
- Other (1)$20.9M4%
Alkermes plc (ALKS) reported revenue of $393M in Q1 2026 (quarter ended Mar 31, 2026), up 28% from the same quarter a year earlier. That came with a gross margin of 84% and net loss of $66M. For the full year FY2025, revenue was $1.48B (−5.2% year on year) and net income $242M. Its largest product in Jun 2026 was Vivitrol at $124M, 23% of the disclosed total, just ahead of Aristada And Aristada Initio at 18%.
Raw charts
11 series · TTMAs reported to the SEC, without any scoring.
Drug Manufacturers - Specialty & Generic
Ranks #20 of 29 by Smart Score